Clinical Relevance of Alkaline Phosphatase Isoenzyme Determinations by High Performance Liquid Chromatography by Schönau, E. et al.
Schönau et al.: Clinical relevance of alkaline phosphatase isoenzymes 641
J. Clin. Chem. Clin. Biochem.
Vol. 24,1986, pp. 641-646
© 1986 Walter de Gruyter & Co.
Berlin · New York
Clinical Relevance of Alkaline Phosphatase Isoenzyme Determinations
by High Performance Liquid Chromatography
By E. Schönau, K, H. Herzog and H.-J. Böhles
Kinderklinik und Poliklinik (Direktor: Prof. Dr. Stehr) der Friedrich-Alexander Universität Erlangen-Nürnberg
(Received November 14, 1985/February 17, 1986)
Summary: A new method for the Separation of alkaline phosphatase isoenzymes by means of high perfor-
mance liquid chromatography (HPLC) is presented. One isoenzyme was identified in homogenate of small
intestine, two were identified in bone, and two in liver, and fragment and biliary isoenzymes were identified
in bile. Sera from 32 patients with different diseases of the skeletal System or the liver were analysed. High
activities of the bone isoenzymes were detected in bone diseases, of the second liver isoenzyme in acute
hepatitis and of the first liver and biliary isoenzymes in biliary obstruction. There are indications that the
first liver isoenzyme is derived from the cell membrane and the second liver isoenzyme from the cytosol. The
biliary isoenzyme is considered to be a highly sensitive and specific indicator for cholestasis.
f Klinische Bedeutung der Isoenzyme der alkalischen Phosphatase bei Bestimmung durch Hochleistungsflüssig'
l keitschromatographie
Zusammenfassung: Beschrieben wird eine neue Methode der Trennung der Isoenzyme der alkalischen Phos-
phatase durch Anwendung der Hochleistungsflüssigkeitschromatographie (HPLC). In Gewebehomogenaten
wurden ein Dünndarm-, zwei Knochen-, zwei Leber^, Abbau- und biliäre Isoenzyme nachgewiesen. Untersucht
wurden 32 Patientenseren mit verschiedenen ossären und hepatischen Erkrankungen. Nachgewiesen wurden
erhöhte Aktivitäten der Knochenisoenzyme bei rachitischen Prozessen, des zweiten Leberisoenzyms bei
akuten Hepatitiden und des ersten Leberisoenzyms sowie biliären Isoenzyms unter Cholestase. Es gibt
l Hinweise, daß das erste Leberisoenzym der membranständigen und das zweite Leberisoenzym der zytosoli-
I sehen Form der Leberphpsphatase entspricht. Diskutiert wird das biliäre Isoenzym als sehr empfindlicher
und spezifischer Indikator für Cholestasen.
°.,uc on · enzyme, which appears in biliary obstruction, and the
Alkaline phosphatase (EC 3.1.3.1) is ä dimeric zinc- Regan isoenzyme, which can be detected in 3 to 15%
containing glycoprotein. It is involved in the trans- of patients with cancer (3). The heterogeneity of the
port of fatty acids, calcium and phosphate across the isoenzymes is partly due to genetic factors and partly
membranes of small intestine (1). Its function in the to posttranslational modifications. MC Kenna et al.
liver still has to be clarified. Under physiological demonstrated the primary structural identity of the
circumstances human senim contains isoenzymes liver, bone and renal isoenzymes and the dissimilarity
derived from liver* bone and small intestine, and in of the placental and intestinal forms (4). Posttransla-
pregnancy from the placenta äs well. Placental alka- tional glycosylation causes variations in pl and is
line phosphatase becomes detectable in serum be- responsible for the differences between liver and bone
tween the 16th and 20th week of gestation (2). Isoen- isoenzymes. The pl of liver isoenzyme is slightly more
zymes considered äs pathqlogical are the biliary iso- acidic than that of bone. The intestinal isoenzyme is
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the most basic and the biliary the most acidic of
all the known forms (5, 6). Hitherto, the alkaline
phosphatase isoenzymes have been measured by
means of chemical inhibitors (7 — 11), heat inactiva-
tion (12) and different electrophoretical methods
(13 — 15). Using immunological methods it is possible
to differentiate between the isoenzyme groups of
bone, liver, kidney and intestine or placenta (16, 17).
Nevertheless none of these methods is satisfactory
for a precise differentiation of the bone from the
liver isoenzyme, which represents the main diagnostic
problem when alkaline phosphatase activities are
pathologically elevated.
In the usual electrophoretic separations, the bone and
liver isoenzymes overlap, owing to their similar pl's.
These separations allow only a visual assesment of
the relative proportions of isoenzymes. Also the heat
inactivation and the chemical Inhibition methods only
permit semiquantitative estimations. We describe a
quick and reproducible method for a clear Separation
of alkaline phosphatase isoenzymes by means of high
Performance liquid chromatography (HPLC).
Methods
The Mono Q HR 5/5-column was equilibrated with 10ml
l mol/1 Tris HC1 buffer pH 8.2 and 5 ml 20 mmol/1 Tris HC1
buffer pH 8.2 at a flow rate of l ml/min. Sera were centrifuged
for five minutes at 8000g. Between one hundred and four
hundred microlitres of serum were· diluted to l ml with 20
mmol/1 Tris HC1. The most precise separations were obtained
with a sample volume of 100 . After application of the sample
to the column, the isoenzymes were eluted stepwise with an
LiCl-gradient (see fig. 1) at a flow rate of l ml/min. Fractions
of 10 drops each were collected. After elution, remnants of
protein were removed from the column with l ml of l mol/1
NaCl. The enzyme activity was constantly measured in 100
fractions. A Substrate concentration of 5 mmol/14-nitrophenyl-
phosphate in 0.5 mol/1 diethanolamine hydrochloride pH 9.8
and in the presence of 0.5 mmol/1 MgCl2 gave a zero order
reaction of isoenzyme activity at 25 °C during the measurement
period of two minutes.
Homogenates of liver, small intestine and vertebral spongiosa
were used for the Identification of isoenzymes. Tissues obtained
within 24 hours post mortem from adult patients were homog-
enized in 20 mmol/1 Tris/HCl buffer pH 8.2, then frozen and
thawed three times. After centrifugation for 15 minutes at
8000 g interfering lipids were removed with Freon. Bile drained
from postcholecystectomy patients was collected and tised for
the identification öf the biliary isoenzyme. The serum fröm
patients with transient hyperphosphatasaemia was heated for
15 minutes at 56 °C to demonstrate the different heat stabilities
of the separäted isoenzymes. Isolated isoenzyme fractions were
treated with 5 mmol/1 Z,-phenylalanine.
Materials and Methods
Materials
For the HPLC-separation, a Gilson Model 302 pump (Abimed,
Düsseldorf, FRG) was used. The gradient was formed by a
11300 ultrograd gradient mixer (LKB, Bromma, Sweden). For
the Chromatographie separations, Pharmacia prepacked Mono
Q HR 5/5 (5 mm 50 mm) columns (Uppsala, Sweden) were
used; these consist of a strong anion exchanger, the charged
group on the gel being -CH2-N(CH3)3". Diethanolamine was
obtained from Fluka (Buchs, Switzerland); Tris, HC1, LiCl, 4-
nitrophenyl phosphate and L-phenylalanine, p. a. grade, from
E. Merck (Darmstadt, FRG).
Results
The sequence of the eluted alkaline phosphatase iso-
enzymes is shown in figure 2. Standard deviatioii of
the peak maximum is s = ±2 fractions. The isoen-
zyme of small intestine jvas eluted first at a LiCl
concentration of 90 mmol/1. In some separations this
isoenzyme overlapped with the first of the bone iso-
zymes. This overlap is demonstrated in the sertun
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Fig. 1. Schematic compilation of methodology used. From top to bottom are the elution time of each LiCl concentration, the
steps of LiCl concentrations and the respectively fräction numbers. For Illustration a fictional elution pattern is used.
J. Clin. Chem. Clin. Biochem. / Vol. 24,1986 / No. 9











20 30 40 50 60 70
Bone
80 90





20 30 40 50 60 70 80 90
e Bile
„Fragment" isoenzymes
1 2 3 4J
Fig. 2.
20 30 40 50 60 70 80 90
Fraction number





a) small intestine homogenate 1200 100
b) serum 287 400
c) vertebral spongiosa homogenate 30 500
d) liver homogenate 1200 200
e) b e fluid 1000 300
second isoenzyme of bone was eluted by 105 mmol/1
LiCl. In sera we could generally identify two liver
isoenzymes. In liver extracts, however, only a small
activity of the rst liver isoenzyme, eluted by 105
mmol/1 LiCl, was detected. The second liver isoen-
zyme was eluted by 130 mmol/1 LiCl. The main bile
fraction fbllowed at LiCl concentrations between
185 — 230 mmol/1. In addition, p to four isoenzyme
peaks were counted between the second liver isoen-
zyme and the biliary isoenzyme; we named these
fragment isoenzymes. By heat inactivation, 95% of
bone and 75% of liver isoenzyme activity were inacti-
vated. Under treatment with 5 mmol/1 JL-phenylalan-
ine, 80% of small intestine, 13% and 12% of bone,
and 14% and 16% of liver isoenzyme activity were
inhibited.
Case Reports
Sera from 32 patients with several types of hepatitis
(n = 8), cholestasis (n = 6), liver cirrhosis (n = 6),
several bone tumours (n == 5), phosphate diabetes
(n = 1), rickets (n = 1), osteomyelitis (n = 2) and
transient hyperphosphatasaemia (n = 3) were exam-
ined and compared with healthy controls (n = 15).
Different isoenzyme patterns were found at different
stages of development (fig. 3). For instance, the isoen-
zyme pattern of a new-born phild is characterized by
high activities of the liver isoenzymes. During infancy
the bone isoenzymes become predominant. After the
growth period of infancy the isoenzymes of liver
remain, while the activities of the bone forms de-
crease.
The distribution of the isoenzyme activities in bone
diseases is presented in figure 4. Separation 9 from a
male infant with phosphate diabetes shows an in-
creased activity of the bone isoenzyme. Separations
10 and 11 show* isoenzyme activities in a case of
osteosarcoma before and after 50 days therapy with
platinex, adriamycin and methotrexate. As a result
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Fig. 3. Serum isoenzyme pattern of normal controls of
different age groups.
Sample
a) serum, o*» 1 day old
b) serum, <J, 11 years old
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Figure 5 shows the isoenzyme activities in cases of
hepatitis and cholestasis. In all examined cases of
hepatitis it was demonstrated that the second liver
isoenzyme represents the major part of the total alka-
i line phosphatase activity. Separation 13 shows the
90 appearance of the biliary isoenzyme during
cholestasis. In this case the isoenzyme activities from
a 20 year-old male patient re sh wn, whose liver
was infiltrated by hydatid cysts. The same patient
| developed cholestasis s a consequence of acute pan-
90 creatitis. The rise of the total alkaline phosphatase
activity was mainly produced by the increase of the
first liver isoenzyme and the appearance of the biliary
isoenzyme.
l T7iorifp» f\ rviv*o^«tc flip* /1f»vp>1/vrvnnp>-nt r^f* icr\f»«m/T«i» or»_
20 30 40 50 60 70 80 90 . . . ^ _ .*V A - , - £ " ...Fraction number tivities in a 9 week-old male mfant, who had hepatitis
B and subsequently developed rickets. Separation 14




a) serum (<J, 1 a) phosphate 788
diabetes
b) serum (<J, 14 a) osteosarcoma 170
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a) hepatitis ( *, 12 a) 1300
semm aciitp ctii<w* ( \
after therapy (...) 280
b) liver (cJ, 20 a) infiltrated by
hydratid cysts
serum, before cholestasis (— ) 780
during cholestasis (...) 2200
r ig. o. aerum isoenzyme pauern in a case aeveiopmeiu 01
Volume combined liver and bone disease (<?, 9 weeks).
(μΐ) Sample Total Volume
activity
100 (U/l) (ul)
100 a) serum, during hepatitis 1600 100
b) serum, 6 weeks later:
hepatitis and rickets 2427 100
100 c) serum, 2 weeks after therapy
100 with Vitamin D " 1800 100
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titis and additional rickets (Separation 15). The
changing pattern of the isoenzyme activities during
therapy with vitamin D is demonstrated in Separation
16. This development shows, that the rise of the
alkaline phosphatase acitivity was caused by an in-
crease of bone isoenzyme and that therapy led to a
reductiön.
Our analysis of three patients with transient hyper-
phosphatasaemia (data not shown) shows that the
activities of all described isoenzymes were elevated,
but the biliary isoenzyme was not detectable.
Discussion
Measurement of the activity of alkaline phosphatase
plays an important role in clinical-chemical diagnosis,
but its usefulness is limited, because the total activity
is composed of several individual isoenzyme activi-
ties. Particulärly the Interpretation of total alkaline
phosphatase activity in paediatric patients is very
difficult. The wide ränge of normal values in the
individual age groups makes it difficult to define
pathological activities of alkaline phosphatase. Deter-
mination of isoenzyme activities becomes essential,
especially in cases of uncertainty. As demonstrated
in figure 6 in combined liver and bone diseases, the
total activity of alkaline phosphatase can only be
conclusive when the activities of isoenzymes are
known. By separating the isoenzymes, the cause of
the increase of alkaline phosphatase activity can be
determined. This example illustrates that the Separ-
ation of alkaline phosphatase isoenzymes is a valu-
able method fpr diagnosis and therapy control in
diseases of liver and bone. This method makes it
possible to reduce the scale of additional diagnostics
(measürement of other liver enzymes, calcium, phos-
phate, parathyrin and radiodiagnosis).
In accordance with our results, Johnson et al. ideiiti-
fied two bone isoenzymes by electrophoresis in poly-
acrylamide (18). Their results confirm the overlap
of the small intestine isoenzyme with the first bone
isoenzyme. They called the first bone isoenzyme
"Growth AP".
Walker et al. fpund two isoenzymes in liver, which
they called "slow-" and "fast liver" (19). Crofton et
al. used ion exchange chromatography tp separate the
biliary isoenzyme. They named it "High Mplecular
Weight Alkaline Phosphatase" (20). The isoenzymes
which are characterized in the literature are cpmpar-
able to the isoenzymes of our Separation method,
except for those we call "fragment isoenzymes". Hi-
therto no such alkaline phosphatase isoenzymes have
been described. With reference to Klein et al., who
reported that alkaline phosphatase isoenzymes are
catabolized in the liver and partially secreted into the
bile (21), we suggest that the fragment isoenzymes
represent catabolites of different isoenzymes.
Heat inactivafion studies show that the bone isoen-
zyme is the most heat sensitive. This corresponds to
the results from Posen et al. (12), who demonstrated
a similar pattern of heat sensitivity. According to
Caspary the bone isoenzyme is particularly important
for the diagnosis of pathological processes of the
bone, because normally bone alterations can only be
detected by radiodiagnosis if the calcium defidency
amounts to 30 — 50% (22). Our examples of phos-
phate diabetes and rickets show pathological activi-
ties for the bone isoenzymes. This is caused by aug-
mented release of calcium and phosphate from bone.
The behaviour of the first and second liver isoen-
zymes is of special interest. Highest activities of the
second liver isoenzyme were found in cases of hepa-
titis. On the other- hand, elevations of the first liver
isoenzyme and the biliary isoenzyme were characteris-
tical of cholestasis. There is evidence in the literature
that the first liver isoenzyme is part of the liver
cell membrane and is removed by bile acids which
accumulate during cholestasis. Schlaeger et al. dem-
onstrated that the alkaline phosphatase äs well äs
other membrane-bound enzymes are more soluble if
the concentration of bile acids is increased (23). The
second liver isoenzyme seems to be localized in the
cytosol. Like other cytosolic enzymes it shows high
serum activities during various forms of cell damage,
such äs hepatitis. Our supposition corresponds to the
results of Simon et al., who showed that alkaline
phosphatase is localized at the membrane äs well äs
in the cytosol of the rat liver cell (24). In addition
they demonstrated that the membrane-bound alka-
line phosphatase activity is increased in bile duct
obstruction, while the cytosolic alkaline phosphatase
remained unaltered. The importance of the biliary
isoenzyme for the diagnosis of cholestasis is known.
In 111 out of 123 cases of cholestasis, Siede et al.
demonstrated that the serum biliary isoenzyme is a
highly specific and sensitive indicator for cholestasis
(25). Its specifity äs an indicator for cholestasis was
even higher than that of LP X. De Broe characterized
the biliary isoenzyme äs a vesicle originating from
fragments of the liver cell membrane during
cholestasis (26). Our own results showed it to be
present in two cases of congenital occlusion of the
bile duct. However both represented advanced cases
with already existing biliary cirrhosis. It will be of
interest to find whether this method is able to discrim-
inate between congenital atresia of the bile duct and
hepatitis of the newborn.
J. Glin. Chem. Clin. Biochem, / Vol. 24,1986 / No. 9
646 Schönau et al.r Clinical relevance of alkaline phosphatase isoenzymes
The advantage of our method for separating the
isoenzymes of alkaline phosphatase is its precision.
This method improves the diagnostic value of the
alkaline phosphatase determination. Moreover it al-
lows the clarification of problems of differential diag-
nosis in liver and böne diseases.
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